Photo of Mary Gay Scanlon
D United States House · District 5 · Pennsylvania On the 2026 ballot

Rep. Mary Gay Scanlon

Compare
Total votes
2,837
all sessions
Attendance
97%
73 missed
Near the chamber average
With party
98%
of cast votes
Higher than 82% of chamber peers
Bipartisan score
1%
crosses aisle rarely
Lower than 82% of chamber peers
Sponsored
1,739
bills & resolutions
Higher than 79% of chamber peers
Committees
5
assignments
1,739 bills and resolutions

Sponsored bills

Total
1,739
Primary
81
Co-sponsor
1,658
This page
1,739
matching current filters
Co-sponsor HRES 878
In committee · Indiana House · Co-sponsor
Recognizing the seriousness of polycystic ovary syndrome (PCOS) and expressing support for the designation of the month of September 2022 as "PCOS Awareness Month".

This resolution expresses support for the goals and ideals of PCOS Awareness Month. Polycystic ovary syndrome (PCOS) is caused by a hormone imbalance. Symptoms can include infertility, weight gain, excess hair growth, and acne.

In committee Jan 20, 2022 1 co-sponsor
Co-sponsor HR 4716
In committee · Indiana House · Co-sponsor
Refuge From Cruel Trapping Act of 2021

Refuge From Cruel Trapping Act of 2021 This bill prohibits, with specified exceptions, the use or possession of body-gripping traps in the National Wildlife Refuge System. The bill imposes on persons who possess or use such traps in the system (1) for a first offense, a civil fine of up to $500 for each body-gripping trap possessed or used; and (2) for subsequent offenses, a civil fine of up to $1,000 for each body-gripping trap possessed or used, imprisonment for up to 180 days, or both such a civil fine and imprisonment. The bill makes any body-gripping traps that are possessed or used in violation of this bill, and any wildlife captured by the use of such traps, including the pelts and raw fur, subject to civil forfeiture. Persons found to be in violation of such prohibition shall pay all associated court costs.

In committee Jan 20, 2022 1 co-sponsor
Co-sponsor HR 6396
In committee · Indiana House · Co-sponsor
Climate RESILIENCE Act

Climate Risk and Emergency Support In Livable Inclusive and Equitable Neighborhoods and Communities Everywhere Act or the Climate RESILIENCE Act This bill makes changes to the Robert T. Stafford Disaster Relief and Emergency Assistance Act to take into account climate change. The bill includes extreme temperature events, such as heat waves or freezes, within the scope of the act and defines resilience for purposes of disaster assistance and mitigation efforts. Federal and state preparedness and mitigation assistance may be used for reducing the impacts of extreme temperatures and improving air quality and mitigating against wildfire smoke.. The bill authorizes implementing predisaster hazard mitigation measures that will be cost-effective and equitable long-term and provide enhanced protection to the community. The Federal Emergency Management Agency (FEMA) must (1) provide technical assistance to underserved and disadvantaged communities for such measures; and (2) provide guidance to implement the latest published editions of relevant consensus-based codes, specifications, and standards that incorporate the latest hazard-resistant designs. The bill includes within the hazard mitigation program requirements the abatement of lead, mold, mildew, radon, asthma, and allergen triggers, or other pollutants and hazardous materials directly caused by a major disaster or emergency. FEMA must report to Congress regarding challenges posed by FEMA requirements for determining the cost-effectiveness of mitigation activities and how such requirements may disproportionately burden underserved or disadvantaged communities.

In committee Jan 14, 2022 1 co-sponsor
Co-sponsor HR 6373
In committee Jan 13, 2022 1 co-sponsor
Co-sponsor HR 6117
In committee · Indiana House · Co-sponsor
PrEP Access and Coverage Act

PrEP Access and Coverage Act This bill requires private health insurance plans to cover prescription drugs that prevent HIV, including related screenings, diagnostic procedures, administrative fees, and clinical follow-ups, without any cost-sharing obligation for the plan holder. Further, insurance plans must not impose any preauthorization requirement for this coverage. These coverage requirements also apply to public health insurance programs, including Medicare, Medicaid, and the Children's Health Insurance Program. Additionally, the bill prohibits denying, limiting, or qualifying coverage or increasing premiums for disability insurance, long-term care insurance, or life insurance policies based on an individual taking medication for HIV prevention. The bill further requires the Department of Health and Human Services to award grants to states, or directly to eligible local organizations, to provide uninsured individuals and underinsured individuals access to prescription drugs and related services that prevent HIV. The Centers for Disease Control and Prevention also must develop a public awareness campaign that focuses efforts in communities with a high need for HIV prevention treatment.

In committee Jan 6, 2022 1 co-sponsor
Co-sponsor HR 3537
Signed into law · Indiana House · Co-sponsor
Accelerating Access to Critical Therapies for ALS Act

Accelerating Access to Critical Therapies for ALS Act This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions. The Department of Health and Human Services (HHS) shall award grants to eligible entities for scientific research utilizing data from expanded access to investigational ALS treatments for individuals who are not otherwise eligible for clinical trials.  The Food and Drug Administration (FDA) shall award grants to public and private entities to cover the costs of research and development of drugs that diagnose or treat ALS and other rare neurodegenerative diseases. HHS shall also establish the Public-Private Partnership for Neurodegenerative Diseases between the National Institutes of Health, the FDA, and at least one eligible entity (generally, an institution of higher education or a nonprofit organization). The partnership shall support the development and regulatory review of drugs that address ALS and other rare neurodegenerative diseases. The FDA shall publish on its website a five-year action plan for fostering the development of drugs that improve or extend the lives of people living with rare neurodegenerative diseases. The Government Accountability Office must report to Congress about the grants provided under this bill, including an analysis of the impact of such grants on research and development of treatments for ALS.

Signed into law Dec 23, 2021 1 co-sponsor
Showing 1,251 to 1,260 of 1,739 bills